1. Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation 
Marco Mielcarek, Barry E. Storer, Mary E.D. Flowers, Rainer Storb, Brenda M. Sandmaier, Paul J. Martin 
Biology of Blood and Marrow Transplantation 
Volume 13, Issue 10, Pages (October 2007)
DOI: /j.bbmt
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Outcome among patients with recurrent high-risk hematologic malignancy after allogeneic HCT. A, Cumulative incidence of remission according to interval from HCT to recurrent malignancy (relapse within 100 days versus days from HCT, P = .05; relapse within 100 days versus >200 days from HCT, P = .04). B, Survival according to interval from HCT to recurrent malignancy (relapse within 100 days versus days from transplantation, P = .01; relapse within 100 days versus >200 days from transplantation, P < .0001). The median follow-up among the 36 surviving patients is 23 (range: 2-115) months. C, Survival according to conditioning intensity (myeloablative versus nonmyeloablative) and interval from HCT to recurrent malignancy.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions